To hear about similar clinical trials, please enter your email below
Trial Title:
The Prognostic Impact Of The Neutrophil To Lymphocyte Ratio In Patients With Locally Advanced Rectal Cancer
NCT ID:
NCT05673343
Condition:
the Prognostic Value of Pre-treatment NLR in Patients With Locally Advenced Rectal Cancer and Post-treatment
Conditions: Official terms:
Rectal Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Summary:
In this study, we aim to investigate the prognostic value of pre-treatment NLR in
patients with locally advenced rectal cancer and post-treatment
Detailed description:
Colorectal cancer (CRC) is the third most common malignancy and the second leading cause
of cancer-related death worldwide.[1] Rectal cancer accounts for 30% to 35% of CRCs[2],
Between 5% and 10% of patients with rectal cancer present with locally advanced rectal
cancer (LARC),[3] Useful and practical prognostic biomarkers obtained before treatment
are anticipated to predict the outcome after main treatment. Such biomarkers will help in
planning strategies for adjustment of postoperative adjuvant therapy.[4]
Inflammation-induced markers play an important role in tumorigenesis and tumor
progression. More evidences had reported systemic inflammation-based biomarkers could be
used to predict tumor behavior.[4] Two convenient and economic measures of systemic
inflammation, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio
(PLR), that reflect the interaction between inflammation and host immune status, making
them potential prognostic factors for various types of cancers. Increased NLR has been
advocated to be an independent prognostic factor for poor survival outcomes in pancreatic
cancer, CRC, and gastric cancer [5-6].
In this study, we aim to investigate the prognostic value of pre-treatment NLR in
patients with locally advenced rectal cancer and post-treatment
Criteria for eligibility:
Study pop:
Patients aged 18-year-old or more 2-Histopathologically proved to be rectal carcinoma. 3-
locally advanced stage II and stage III according to AJCC TNM staging 8th edition 4- fit
for concurrent chemoradiation therapy (CCRT) with adequate organ function.
5- Performance status 0-1 according to ECOG PS
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Patients aged 18-year-old or more 2-Histopathologically proved to be rectal
carcinoma. 3- locally advanced stage II and stage III according to AJCC TNM staging
8th edition 4- fit for concurrent chemoradiation therapy (CCRT) with adequate organ
function.
5- Performance status 0-1 according to ECOG PS
Exclusion Criteria:
- 1- metastatic disease 2- Younger than 18 year old 3-Any other malignancy 4-There is
contraindication for CCRT
Gender:
All
Minimum age:
18 Years
Maximum age:
90 Years
Healthy volunteers:
No
Start date:
January 4, 2023
Completion date:
March 1, 2024
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05673343
